Phase II pilot trial of non-myeloablative allogeneic peripheral blood stem cell (PBSC) transplantation using fludarabine, low dose TBI and post-transplant cyclosporine and mycophenolate mofetil followed by donor lymphocyte infusion for therapy of advanced or metastatic human papilloma virus (HPV) - Associated cervical carcinoma refractory to standard therapy.

Trial Profile

Phase II pilot trial of non-myeloablative allogeneic peripheral blood stem cell (PBSC) transplantation using fludarabine, low dose TBI and post-transplant cyclosporine and mycophenolate mofetil followed by donor lymphocyte infusion for therapy of advanced or metastatic human papilloma virus (HPV) - Associated cervical carcinoma refractory to standard therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Fludarabine (Primary) ; Ciclosporin; Mycophenolate mofetil
  • Indications Cervical cancer; Graft-versus-host disease; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2009 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top